Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.The company has 3 R&D and 5 manufacturing facilities.
What Alembic files
- Others153
- Updates64
- Investor Meet40
- Important39
- Dividend/Bonus19
- Board Meeting15
Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited s Bioequivalence Facility in Vadodara, Gujarat
Alembic Pharmaceuticals has expanded its global footprint by incorporating a new wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai. This move aims to explore fresh business opportunities and strengthen the international promotion, sale, and distribution of the company’s pharmaceutical portfolio through a cash investment.
Alembic Pharma reported strong Q1 FY27 results: Revenue up 26% to Rs 2150 Cr, PAT up 12% to Rs 173 Cr. Growth was broad-based, with US Formulation up 49% and API up 33%. New launches and ANDA approvals drove performance. An investor call is scheduled.
Alembic Pharma reported strong Q1 results. Revenue rose 26% to Rs 2150 Cr, PAT up 12% to Rs 173 Cr. EBITDA margin at 24%. US Formulation surged 49% with 7 launches, India Branded grew 7% (3 new products), and API business was up 33%. Received 10 ANDA approvals.
Alembic Pharma received USFDA final approval for Prucalopride Tablets, for chronic constipation. The drug targets an estimated market of ~₹830 Cr, providing a significant new opportunity.